Posts Tagged ‘Tom Insel’

Cure Alliance Letter to the New York Times

In response to the New York Times’s profile on NIMH Director Tom Insel, Cure Alliance cofounders Hakon Heimer and Robin Cunningham joined with Nobel laureate and Cure Alliance Advisor James Watson on a letter to the editor to point out that Insel’s challenge of trying to please diverse and competing constituencies would be a lot easier if he had resources necessary for the task. Here is the full letter: To the editor: Dr. Tom Insel’s challenging job (“Blazing Trails in Brain Science,” Science, Feb 4) would be easier if the National Institute of Mental Health were not running on a shoestring. The Institute’s 2012 budget was $1.5 billion, which seems like a lot until you consider how much mental illnesses cost us: the 2010 US Burden of Disease study shows that the burden to Americans is about equal to that of cancer. As the nation’s economy strengthens in the next few years, we urge policymakers to bring NIMH’s budget closer […]

Read More »

Research Priorities at NIMH

by Robin Cunningham On February 8, 2013, I attended the National Institute for Mental Health (NIMH) Alliance for Research Progress Meeting held at NIMH Headquarters in the Neuroscience Center, Rockville, MD.  The purpose of these semi-annual meetings is to assist advocacy organizations in staying abreast of current and on-going research into the causes, treatments, prevention and cures for the various brain disorders, including mental illnesses, for which they advocate. The organizations at the meeting represent a wide array of brain disorders, but Cure Alliance for Mental Illness was the only non-profit in attendance that focuses its efforts entirely on advocating for increased funding for research for all mental illnesses. More information about this February 8th meeting, including an agenda, a summary of the presentations made, and a list of attendees, is available at the NIMH website. Thomas R. Insel, M.D., director of the NIMH, gave a presentation entitled “The State […]

Read More »